Fate Therapeutics Inc
FATE1.130USD
+0.010+0.89%
Market hours （ET）Quotes delayed by 15 min
130.33MMarket Cap
LossP/E TTM
More Details of Fate Therapeutics Inc Company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Fate Therapeutics Inc Info
Ticker SymbolFATE
Company nameFate Therapeutics Inc
IPO dateOct 01, 2013
CEOValamehr (Bahram)
Number of employees181
Security typeOrdinary Share
Fiscal year-endOct 01
Address12278 Scripps Summit Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92131
Phone18588751803
Websitehttps://fatetherapeutics.com/
Ticker SymbolFATE
IPO dateOct 01, 2013
CEOValamehr (Bahram)
Company Executives of Fate Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Mr. Kamal Adawi
Mr. Kamal Adawi
Chief Financial Officer
Chief Financial Officer
75.00K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Mr. Kamal Adawi
Mr. Kamal Adawi
Chief Financial Officer
Chief Financial Officer
75.00K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Redmile Group, LLC
11.16%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.63%
BlackRock Institutional Trust Company, N.A.
7.36%
Wilshire Advisors LLC
7.36%
Other
57.56%
Shareholders
Shareholders
Proportion
Redmile Group, LLC
11.16%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.63%
BlackRock Institutional Trust Company, N.A.
7.36%
Wilshire Advisors LLC
7.36%
Other
57.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
35.47%
Investment Advisor
29.79%
Hedge Fund
8.07%
Venture Capital
3.31%
Research Firm
2.58%
Individual Investor
1.52%
Pension Fund
0.13%
Family Office
0.12%
Bank and Trust
0.11%
Other
18.91%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
362
90.58M
121.91%
--
2025Q3
392
90.63M
123.83%
-62.33K
2025Q2
417
90.67M
126.20%
-17.10M
2025Q1
428
107.83M
118.91%
-28.45M
2024Q4
466
102.82M
135.16%
-13.40M
2024Q3
501
116.61M
140.28%
-7.11M
2024Q2
512
123.74M
135.30%
-845.14K
2024Q1
525
124.52M
115.54%
-6.97M
2023Q4
539
96.81M
133.02%
-789.66K
2023Q3
563
97.53M
144.16%
-13.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Redmile Group, LLC
12.88M
11.17%
+11.33K
+0.09%
Jul 02, 2025
ARK Investment Management LLC
10.31M
8.94%
+10.31M
--
Mar 31, 2025
The Vanguard Group, Inc.
8.77M
7.6%
-1.54M
-14.97%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.61M
7.47%
+225.50K
+2.69%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.93%
--
--
Jun 30, 2025
Acadian Asset Management LLC
2.46M
2.13%
-13.61K
-0.55%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.43M
2.11%
+159.56K
+7.03%
Jun 30, 2025
Vestal Point Capital, LP
2.52M
2.18%
-850.00
-0.03%
Jun 30, 2025
State Street Investment Management (US)
2.23M
1.93%
+119.06K
+5.64%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.7%
WisdomTree BioRevolution Fund
0.28%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
WisdomTree BioRevolution Fund
Proportion0.28%
iShares Micro-Cap ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Fate Therapeutics Inc?
The top five shareholders of Fate Therapeutics Inc are:
Redmile Group, LLC holds 12.88M shares, accounting for 11.17% of the total shares.
ARK Investment Management LLC holds 10.31M shares, accounting for 8.94% of the total shares.
The Vanguard Group, Inc. holds 8.77M shares, accounting for 7.60% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.61M shares, accounting for 7.47% of the total shares.
Johnson & Johnson Innovation-JJDC, Inc. holds 3.38M shares, accounting for 2.93% of the total shares.
Redmile Group, LLC holds 12.88M shares, accounting for 11.17% of the total shares.
ARK Investment Management LLC holds 10.31M shares, accounting for 8.94% of the total shares.
The Vanguard Group, Inc. holds 8.77M shares, accounting for 7.60% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.61M shares, accounting for 7.47% of the total shares.
Johnson & Johnson Innovation-JJDC, Inc. holds 3.38M shares, accounting for 2.93% of the total shares.
What are the top three shareholder types of Fate Therapeutics Inc?
The top three shareholder types of Fate Therapeutics Inc are:
Redmile Group, LLC
ARK Investment Management LLC
The Vanguard Group, Inc.
Redmile Group, LLC
ARK Investment Management LLC
The Vanguard Group, Inc.
How many institutions hold shares of Fate Therapeutics Inc (FATE)?
As of 2025Q4, 362 institutions hold shares of Fate Therapeutics Inc, with a combined market value of approximately 90.58M, accounting for 121.91% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.92%.
What is the biggest source of revenue for Fate Therapeutics Inc?
In --, the -- business generated the highest revenue for Fate Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
